Ann: IMU Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx, page-28

Ahjay you are 100% correct
As we can see by the share price, my reasons for liking this company are not the same as some other shareholders views, if it were the share price would be a lot higher.

This difference in opinion is probably one the reasons why I hold somewhere between 25 and 35 million shares in this stock while according to the annual report most others ( 54% of shareholders) hold only 100,000 or less.

So in my view the biggest problem is to there are too many small holdings (54% of share holders have 100,000 or less shares) between them they own 23% of the company stock In my view small holders generally don't see the significance of any given announcement until usually some significant time latter by which time the share price is significantly different.

My post was introduced as being My reasons for liking these shares
I wasn't trying to post what other peoples reasons might be for not placing the same value on these shares as myself,

I have been looking at and invested in Biotech for a number of years and there are a number of possible outcomes that could eventuate.

In my view I see lots of different factors that have been coming together which in my view significantly de-risk this share and continue to do so, so much so ( in my view ) that the risk of clinical failure (in my view) is probably now less than the risk of a take over, that's not to say that clinical failure would not be worse, just in my view less likely.

In my view if the clinical trials continue to be successful, then the best way forwards after in order to build maximum shareholder value, as opposed to a takeover, is with marketing deals, It has happened before, and it could happen again, and hopefully someday "marketing deals" will happen for Imugene.

Paul Hopper in recent times has been buying shares, and I think he probably has a good inside view of this company, he has himself made hints about licencing deals as an aspiration or goal for Imugenes products. https://www.yourmoney.com.au/watch/imugene-trading-day/

I can also assure you that Paul Hopper and others in the top 20 holders are not the only ones developing a positive view of Imugenes products and future

hope that helps

kind regards
fp